Unlike most of her Senate colleagues involved in the stock market, who focus on high-flying technology equities, Minnesota Senator Tina Smith maintains a unique portfolio with a significant interest in healthcare.
Indeed, key players in her portfolio have recorded positive gains in the past year, raising questions regarding her motivation for picking specific stocks.
It’s worth noting that despite maintaining a unique portfolio, Smith has come under scrutiny regarding allegations of utilizing insider information in her trades.
Picks for you
For instance, back in 2022, Smith was implicated in a report that alleged her Senate trades over the past few years involved companies that intersected with her congressional committees.
Receive Signals on US Senators' Stock Trades
Stay up-to-date on the trading activity of US Senators. The signal triggers based on updates from the Senate disclosure reports, notifying you of their latest stock transactions.
In this context, Smith’s husband, an investor in medical device companies, held shares in two insulin equipment manufacturers when she joined the Senate in 2018. While the senator has advocated for affordable insulin, it’s unclear how price cuts would have affected these companies.
Smith stock portfolio performance
Among the standout performers in Smith’s portfolio is Tactile Systems Technology (NASDAQ: TCDM), which has rallied an impressive 28.70% in the past year. The company’s medical technology solutions for managing chronic conditions have seen rising demand, driving its stock price higher.
Another notable performer is Artivion, which has surged 55.23% in 2024. Artivion, specializing in cardiovascular solutions, has benefited from strong financial results and strategic acquisitions, pushing its stock higher.
NextEra Energy (NYSE: NEE), a key player in renewable energy, has also delivered solid returns, rising by 16.48% over the year. The company’s continued expansion in wind and solar projects has fueled this growth.
Lastly, Insulet Corporation, known for its innovative insulin pump technology, has posted a 27.34% increase in its stock price. As diabetes continues to be a growing global health issue, Insulet’s solutions for improving patient care have resonated well with investors.
Senator Smith’s portfolio returns
If you had an investment of $1,000 and evenly distributed it across the four stocks, each equity would have received $250. The $250 you invested in Tactile Systems Technology would now be worth approximately $321.75.
Similarly, your $250 investment in Artivion would have grown to $388.08, while the $250 allocated to NextEra Energy would now be valued at $291.20. Finally, your $250 investment in Insulet would now be worth $318.35.
Altogether, your portfolio would now be worth $1,319.38, reflecting a cumulative return of 31.94% for the year.
In summary, the highlighted stocks provide a concise overview of Smith’s significant investments. They are intended to serve as an example, as most investors typically achieve better results with a more focused portfolio, avoiding excessive diversification.
Featured image via Shutterstock
